Home / Health / The US jury calls on AbbVie to pay $ 3 million for AndroGel's retrial

The US jury calls on AbbVie to pay $ 3 million for AndroGel's retrial

NEW YORK (Reuters) – An American jury on Monday ordered AbbVie Inc. to pay more than $ 3 million to a man claiming that the company misrepresented the risks of its testosterone surrogate AndroGel and misrepresented it Heart attack suffered The jury did not hold AbbVie strictly liable.

FILE PHOTO: A screen shows the share price of the pharmaceutical company AbbVie on the floor of the New York Stock Exchange on July 18, 2014. REUTERS / Brendan McDermid

The ruling of the Federal Court in Chicago fell in the second trial The US District Judge Matthew Kennelly passed a $ 1

50 million judgment in December over "logically incompatible" judgments.

It is the second judgment against AbbVie in the consolidated litigation over testosterone replacement products by Chicago-based company and other drug manufacturers. More than 6,000 similar lawsuits have been filed, most of them against AbbVie.

In a separate study, a federal jury in January found AbbVie unresponsive in a lawsuit filed by a man from Arizona who claimed to have suffered a pulmonary embolism from AndroGel.

According to court records, the jury on Monday concluded that AbbVie had not misrepresented the drug and was not strictly liable, but that the company had acted negligently.

He awarded Mitchell $ 200,000 in damages and $ 3 million in punitive damages.

AbbVie said in a statement that he was disappointed with the verdict and wanted to appeal.

Mitchell lawyers did not immediately respond to requests for comment on the verdict.

After nearly five years of treatment with AndroGel, Mitchell suffered a heart attack in 2012, but recovered after several months.

In AndroGel's first decision against AbbVie, a jury in October ordered the company to pay more than $ 140 million to a Tennessee man who claimed the drug caused a heart attack. AbbVie has asked Kennelly to dismiss this ruling on disagreements during the trial.

Other drug companies are facing similar complaints about their testosterone replacement therapies.

But Eli Lilly and Co, Endo International and GlaxoSmithKline have told Kennelly in recent months that they have now completed hundreds of lawsuits against them. The terms of these comparisons were not disclosed.

More than 4,000 cases are pending against AbbVie.

Reporting by Tina Bellon; Edited by Leslie Adler

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *